var data={"title":"Prucalopride (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Prucalopride (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/495910?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=prucalopride-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Prucalopride (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13761703\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Resotran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826948\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Serotonin 5-HT<sub>4</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827120\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic idiopathic constipation:</b> Females or males (off-label population [Yiannakou 2015]): Oral: 2 mg once daily;<b> Note: </b>If no bowel movement within 3 to 4 days, consider adjunctive laxative therapy for acute treatment. Discontinue use if therapy is not effective within 4 weeks of initiation. Reassess for therapeutic benefit at regular intervals if prolonged therapy (&gt;3 months) is needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827121\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic idiopathic constipation: </b>Females &gt;65 years or males &ge;65 years (off-label population [Yiannakou 2015]): Oral: Initial: 1 mg once daily; may increase to 2 mg once daily if necessary;<b> Note:</b> If no bowel movement within 3 to 4 days, consider adjunctive laxative therapy for acute treatment. Discontinue use if therapy is not effective within 4 weeks of initiation. Reassess for therapeutic benefit at regular intervals if prolonged therapy (&gt;3 months) is needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827123\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GFR &lt;30 mL/minute/1.73 m<sup>2</sup>: 1 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Use is contraindicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827122\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Initial: 1 mg once daily; may increase to 2 mg once daily if needed and well tolerated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827128\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Resotran: 1 mg, 2 mg [contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13761702\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827124\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer without regard to meals. If a dose is missed, do not double to make up for a missed dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826950\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic idiopathic constipation:</b> Treatment of chronic idiopathic constipation in adult females with inadequate response to laxatives</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471494\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic constipation in men; Opioid-induced constipation in patients with chronic pain (noncancer)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826947\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Resotran may be confused with Restoril</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826988\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (17%), abdominal pain (12%), diarrhea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4%), fatigue (3%), malaise (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pollakiuria (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Flatulence (5%), upper abdominal pain (5%), vomiting (5%), dyspepsia (3%), abnormal bowel sounds (2%), anorexia (1%), gastroenteritis (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Amnesia, angina pectoris, anxiety, atrial arrhythmia, bronchitis, cardiac arrhythmia, chest pain, cholecystitis, cholelithiasis, confusion, constipation, depression, dyspnea, hyperhidrosis, loss of balance, migraine, myocardial infarction, ovarian cyst, palpitations (Anton 2017), pancreatitis, pneumonia, sinusitis, stomach discomfort, suicidal ideation (Anton 2017), supraventricular tachycardia, syncope, tremor, urinary incontinence, urinary tract infection, vaginal hemorrhage, visual hallucinations (Anton 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826955\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to prucalopride or any component of the formulation; renal impairment requiring dialysis; intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the GI tract (eg, Crohn disease, ulcerative colitis, toxic megacolon/megarectum).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826956\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression (particularly during the first day of treatment), which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: If severe or persistent diarrhea occurs, discontinue therapy and advise patient to consult health care provider. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic colitis: May occur (rare); discontinue therapy if severe, persistent, and/or worsening abdominal symptoms, bloody diarrhea, or rectal bleeding develops and advise patient to consult health care provider. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of arrhythmias, ischemic cardiovascular disease, pre-excitation syndromes (eg, Wolff-Parkinson-White syndrome), or A-V nodal rhythm disorders. Slight increases in heart rate and shortened PR intervals  have been observed; treatment-related effects on QRS duration or QTc interval were not observed. Palpitations have also been observed; monitoring of cardiovascular status is recommended. Instruct patients to report severe or persistent palpitations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant disease: Use with caution in patients with severe and unstable concomitant disease (eg, cancer, AIDS, neurological or psychiatric, pulmonary, insulin-dependent diabetes mellitus or other endocrine disorders); has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment (Child-Pugh class C); initial dose reduction is recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; prucalopride mainly undergoes renal elimination. Dose reduction is required in severe impairment; contraindicated in patients requiring dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly (limited data); dose reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Males: Efficacy not established in males (clinical trials had an insufficient number of males to determine efficacy); however, a potential benefit has been observed in some studies (Yiannakou 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: May contain lactose; do not use in patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853604\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853602\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83328&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Prucalopride may decrease the serum concentration of Estrogen Derivatives (Contraceptive). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Prucalopride.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Prucalopride may decrease the serum concentration of Progestins (Contraceptive). <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13826953\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Spontaneous abortion has been observed in pregnant women during clinical trials, although a causal association with prucalopride has not been established. Use during pregnancy is not recommended. Women of childbearing potential should employ effective contraception during therapy. An additional method of contraception is recommended for patients experiencing severe diarrhea and receiving oral contraceptives due to the potential for decreased efficacy of the oral contraceptive; cases of unintended pregnancies have been reported with prucalopride. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099917\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Prucalopride is excreted in breast milk. Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827127\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Cardiovascular symptoms (eg, palpitations) particularly in patients with cardiovascular disease; frequency of bowel movements</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827005\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Prucalopride is a selective, high affinity 5-HT<sub>4</sub> receptor agonist whose action at the receptor site promotes cholinergic and nonadrenergic, noncholinergic neurotransmission by enteric neurons leading to stimulation of the peristaltic reflex, intestinal secretions, and gastrointestinal motility.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13827059\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 567 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Minor route of elimination; 8 metabolites produced (<i>in vitro</i> data suggest that 4 of 8 metabolites have lower or similar affinity to prucalopride for 5-HT<sub>4</sub> receptor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~24 hours; terminal half-life increases to 34, 43, and 47 hours in mild, moderate, and severe renal impairment, respectively</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily as unchanged drug: Urine (55.1% to 73.8%); feces (3.7% to 8.1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190118\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Resolor (AE, AT, BE, BR, CH, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, HK, HR, IE, IL, JO, KR, LB, LT, LU, MT, NL, NO, PE, PH, PL, PT, QA, RO, SE, SG, SK, TH, TR, VN);</li>\n      <li>Resotrans (AU, CR, DO, GT, HN, MX, NI, NZ, PA, SV);</li>\n      <li>Rezolor (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Anton C, Crawford C. Adverse effects of laxatives: update. <i>Wolters Kluwer Adverse Drug Reaction Bulletin</i>. 2017;303.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camilleri M, Kerstens R, Rykx A, et al, &ldquo;A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation,&rdquo; <i>N Engl J Med</i>, 2008, 358(22):2344-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prucalopride-united-states-not-available-drug-information/abstract-text/18509121/pubmed\" target=\"_blank\" id=\"18509121\">18509121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Resotran (prucalopride) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20428949\"></a>Sloots CE, Rykx A, Cools M, et al, &ldquo;Efficacy and Safety of Prucalopride in Patients With Chronic Noncancer Pain Suffering from Opioid-Induced Constipation,&rdquo; <i>Dig Dis Sci</i>, 2010, 55(10):2912-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prucalopride-united-states-not-available-drug-information/abstract-text/20428949/pubmed\" target=\"_blank\" id=\"20428949\">20428949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25869393\"></a>Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation. <i>Am J Gastroenterol.</i> 2015;110(5):741-748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/prucalopride-united-states-not-available-drug-information/abstract-text/25869393/pubmed\" target=\"_blank\" id=\"25869393\">25869393</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83328 Version 63.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13761703\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13826948\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13827120\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F13827121\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13827123\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13827122\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F13827128\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F13761702\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13827124\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13826950\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471494\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13826947\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13826988\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13826955\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13826956\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13853604\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13853602\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13826953\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21099917\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13827127\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13827005\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13827059\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190118\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83328|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=prucalopride-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Prucalopride (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}